Investor Presentaiton

LOVVOLUS DESIGNED TO COMPETE CLINICALLY WITH THE MARKET LEADER EUROPEAN & CANADIAN PHASE III STUDY EUROPEAN & CANADIAN GLABELLAR LINE PHASE III STUDY PRIMARY ENDPOINT: NON-INFERIORITY RESPONDER RATE DAY 30 PLACEBO BOTOX® JEUVEAUⓇ All 32.7% 41.9% 37.6% Related 4.1% 14.6% 15.5% 87.2% 82.8% SAFETY PROFILE-ADVERSE EVENTS Drug-Related None Other AEs of Interest Ptosis (drug-related) Eyelid-Jeuveau 1.6%, Botox 0% Eyebrow-Jeuveau 0%, Botox 0% Source: Data from Evolus clinical trial EVB-003 1. Glabellar Line Scale JEUVEAUⓇ n=235 4.2% BOTOX® n=244 PLACEBO n=48 GLS1 = None or mild glabellar wrinkles at max frown investigator assessment 5

View entire presentation